Clin2
NCT06364774Possibly a fitRecruiting

Gene therapy for transfusion-dependent beta thalassemia

Beta-Thalassemia

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This gene therapy trial uses a modified virus to deliver a healthy gene into your own stem cells. The goal is to help your body make normal red blood cells so you may need fewer or no transfusions.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
12 people
Ages
18 years to 40 years
Study type
Interventional

Who can take part

  • You are between 18 and just under 40 years old
  • You have a severe form of beta thalassemia that requires regular blood transfusions
  • You have not had a bone marrow or stem cell transplant before
  • You have no active cancer or other serious health conditions that would make the treatment risky
  • You are willing to discuss other treatment options with your doctor before joining

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03351829Not yet recruiting
Gene therapy for beta thalassemia using a modified virus

This trial tests a new gene therapy that uses a modified virus to add a working copy of the gene for beta globin, which may help your body make healthy red blood cells. It is designed for people with beta thalassemia who have not had a bone marrow transplant and do not have a matching sibling donor.

Shenzhen, Guangdong
NCT06647979Recruiting· Phase 1
Gene editing for severe sickle cell or thalassemia

This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.

Boston, Massachusetts
NCT07680803Recruiting· Phase 2
Gene therapy for transfusion-dependent beta-thalassemia

This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.

Rome, Lazio
NCT06219239Recruiting
Gene therapy for transfusion-dependent beta-thalassemia

This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.

Tianjin, Tianjin Municipality
NCT06655662Recruiting· Phase 1
Gene therapy for severe beta-thalassemia

This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.

Guangxi
NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia

This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.

Shanghai

Hear when a new Beta-Thalassemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.